• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

RANKL Signaling Pathway in Oncology Drug Pipeline Update 2015

  • ID: 2067700
  • June 2015
  • Region: Global
  • Bioseeker

Receptor activator of nuclear factor-kappa B ligand (RANKL) is a member of tumor necrosis factor (TNF) superfamily. It binds to Receptor activator of NF-kB (RANK) and plays a major role in the regulation of osteoclast function. Binding of RANKL to RANK leads to the activation of signaling modules such as NF-kappa B, mitogen activated protein kinases (MAPK's), protein kinase C (PKC), Ca2+/Calcineurin/nuclear factor of activated T cells (NFAT) and phosphatidyl 3-kinase (PI3K). The RANKL-RANK signaling system is negatively regulated by a decoy receptor known as Osteoprotegerin.
There are today 261 companies plus partners developing 322 RANKL pathway targeting drugs in 1346 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 172 drugs. Rankl Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 150 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 150 out of the 150 studied drug targets so far have been READ MORE >

Note: Product cover images may vary from those shown

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)